Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Stanford University
City of Hope Medical Center
Thomas Jefferson University
Takeda
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Brown University
Acerta Pharma BV
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Case Comprehensive Cancer Center
City of Hope Medical Center
Case Comprehensive Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
National Institutes of Health Clinical Center (CC)
AbbVie
Bristol-Myers Squibb
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Dana-Farber Cancer Institute
Masonic Cancer Center, University of Minnesota
Celgene
Thomas Jefferson University
UNC Lineberger Comprehensive Cancer Center
Pharmacyclics LLC.
M.D. Anderson Cancer Center
BeiGene
GlaxoSmithKline
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
OrphAI Therapeutics
Daiichi Sankyo
City of Hope Medical Center
Amgen
Kyowa Kirin Co., Ltd.
Amgen
M.D. Anderson Cancer Center
City of Hope Medical Center
Arog Pharmaceuticals, Inc.
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
M.D. Anderson Cancer Center
Pfizer
Jazz Pharmaceuticals
National Institutes of Health Clinical Center (CC)
University of Nebraska
Alliance for Clinical Trials in Oncology
National Institutes of Health Clinical Center (CC)
Therapeutic Advances in Childhood Leukemia Consortium